{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:08Z","timestamp":1791357848213,"version":"4.3.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"DOI":"10.13039\/100006591","name":"FibroGen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006591","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>We evaluated the efficacy and cardiovascular safety of roxadustat versus placebo by analyzing data pooled from three phase 3 studies of roxadustat in patients with non\u2013dialysis-dependent CKD and CKD-related anemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>In the three phase 3, double-blind studies of roxadustat versus placebo evaluating the treatment of CKD-related anemia in patients not requiring dialysis, the primary efficacy end point was mean change from baseline in hemoglobin averaged over weeks 28\u201352, regardless of rescue therapy. The primary cardiovascular safety end point was a composite measure of major adverse cardiovascular events (MACE; all-cause mortality, myocardial infarction, stroke). MACE plus (MACE+; MACE plus unstable angina and heart failure requiring hospitalization) and all-cause mortality were key secondary safety end points. These safety end points were adjudicated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 4277 patients with non\u2013dialysis-dependent CKD were randomized (roxadustat,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =2391; placebo,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =1886). Baseline characteristics were comparable between groups; the mean (SD) hemoglobin was 9.1 (0.7) g\/dl and mean eGFR was 20 (12) ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . Patients treated with roxadustat versus those treated with placebo showed a mean change from baseline in hemoglobin averaged over weeks 28\u201352, regardless of rescue therapy, of 1.9 versus 0.2 g\/dl, a treatment difference of 1.7 (95% confidence interval [95% CI], 1.7 to 1.8). Roxadustat reduced the need for red blood cell transfusion in the first 52 weeks versus placebo (6.1 versus 20.4 per 100 patient-exposure years, respectively; hazard ratio [HR], 0.26; 95% CI, 0.21 to 0.32). There were no increased risks of MACE (HR, 1.10; 95% CI, 0.96 to 1.27), MACE+ (HR, 1.07; 95% CI, 0.94 to 1.21), all-cause mortality (HR, 1.08; 95% CI, 0.93 to 1.26), or individual MACE+ components in patients treated with roxadustat versus those treated with placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Roxadustat was more effective than placebo at increasing hemoglobin in patients with non\u2013dialysis-dependent CKD and anemia, while decreasing transfusion rate and being noninferior to placebo with respect to risk of MACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial registry name and registration number:<\/jats:title>\n                    <jats:p>A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis, NCT01750190; Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS), NCT01887600; Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis, NCT02174627<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.16191020","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T15:25:12Z","timestamp":1628263512000},"page":"1190-1200","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":82,"title":["Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non\u2013Dialysis-Dependent CKD"],"prefix":"10.2215","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct01750190","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01887600","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02174627","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01750190","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01887600","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02174627","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robert","family":"Provenzano","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Szczech","sequence":"additional","affiliation":[{"name":"FibroGen, Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Leong","sequence":"additional","affiliation":[{"name":"FibroGen, Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil G.","family":"Saikali","sequence":"additional","affiliation":[{"name":"FibroGen, Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhong","sequence":"additional","affiliation":[{"name":"FibroGen, Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyson T.","family":"Lee","sequence":"additional","affiliation":[{"name":"FibroGen, Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-0237","authenticated-orcid":false,"given":"Dustin J.","family":"Little","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Houser","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Frison","sequence":"additional","affiliation":[{"name":"AstraZeneca, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Houghton","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Neff","sequence":"additional","affiliation":[{"name":"FibroGen, Inc., San Francisco, California"},{"name":"Deceased."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.kisu.2017.09.002","article-title":"New options for the anemia of chronic kidney disease","volume":"7","author":"Coyne","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"key":"B2-20241015","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.ajkd.2013.05.004","article-title":"RBC transfusions among hemodialysis patients (1999-2010): Influence of hemoglobin concentrations below 10 g\/dL","volume":"62","author":"Gilbertson","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000455387","article-title":"History of erythropoiesis-stimulating agents, the development of biosimilars, and the future of anemia treatment in nephrology","volume":"45","author":"Kalantar-Zadeh","year":"2017","journal-title":"Am J Nephrol"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1111\/hdi.12567","article-title":"HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism","volume":"21","author":"Haase","year":"2017","journal-title":"Hemodial Int"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","article-title":"Purification and characterization of hypoxia-inducible factor 1","volume":"270","author":"Wang","year":"1995","journal-title":"J Biol Chem"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: Harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019b","journal-title":"N Engl J Med"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019a","journal-title":"N Engl J Med"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: A randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/1744-9987.13468","article-title":"Oral roxadustat three times weekly in ESA-na\u00efve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000508100","article-title":"A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoeisis-stimulating agent-naive chronic kidney disease patients not on dialysis","volume":"144","author":"Akizawa","year":"2020","journal-title":"Nephron"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B21-20241015","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, double-blind, placebo-controlled study (ALPS) [published online ahead of print February 25, 2021]","author":"Shutov","journal-title":"Nephrol Dial Transplant"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/kisup.2015.2","article-title":"United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease","volume":"5","author":"Collins","year":"2015","journal-title":"Kidney Int Suppl (2011)"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1203166","article-title":"Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis","volume":"368","author":"Macdougall","year":"2013","journal-title":"N Engl J Med"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/nep.12713","article-title":"Progression and outcomes of non-dialysis dependent chronic kidney disease patients: A single center longitudinal follow-up study","volume":"22","author":"Khan","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2215\/CJN.06020809","article-title":"Transfusion burden among patients with chronic kidney disease and anemia","volume":"5","author":"Lawler","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.16191020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:24Z","timestamp":1786369404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.16191020"}},"subtitle":["Pooled Results of Three Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.16191020","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"2020-10-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}